Pursuant to regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements), 2015, we are enclosing herewith the Press Release and Management Discussion & Analysis of the Company for the Fourth Quarter ended March 31, 2026.
GLENMARK · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Glenmark Pharmaceuticals reported strong Q4 FY26 results with consolidated revenue of INR 37,706 million (+15.8% YoY) and full-year revenue of INR 169,825 million (+27.5% YoY). FY26 EBITDA stood at INR 45,724 million with an EBITDA margin of 26.9%, while PAT for the year was INR 13,620 million (7.8% margin). The standout development was a landmark AbbVie licensing deal for ISB 2001 (BEAT® protein platform) with a USD 700 million upfront payment and potential total deal value of USD 1.925 billion, which drove North America revenue up 136.6% to INR 71,390 million. However, India revenue declined 17% YoY to INR 37,237 million. Glenmark also settled antitrust litigation in the US for USD 29.628 million over 5 years without admission of liability.
The strong 27.5% full-year revenue growth and landmark AbbVie deal signal Glenmark's innovation pipeline is gaining global recognition, which could be positive for the stock. The India revenue decline and antitrust settlement are concerns to monitor.